Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE-2 phase 3 trial of cabazitaxel and pelvic radiotherapy in high-risk localized prostate cancer
MOH_2018-12-11_004839Phase 3Not yet recruiting
- Sponsor
- Unicancer
- Start
- Jan 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabazitaxel in prostate cancer (PCa) (4 arms), sponsored by Unicancer. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2018-12-11_004839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-11_004839.